Mohammad Reza Alivand

Mohammad Reza Alivand

Auto-generated profile, based on publicly available information

Mohammad Reza Alivand

Eye Research Center, The Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MFMasoumeh Fardi
Masoumeh Fardi
MAMohammadreza Alivand
Mohammadreza Alivand
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
MHMajid Farshdousti Hagh
Majid Farshdousti Hagh
SSSaeed Solali
Saeed Solali

7 September 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MZMaryam Zare
Maryam Zare
Milad BastamiMilad Bastami
Milad Bastami
SSSaeed Solali
Saeed Solali
MAMohammad Reza Alivand
Mohammad Reza Alivand

14 October 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
YKYaser Khajebishak
Yaser Khajebishak
LPLaleh Payahoo
Laleh Payahoo
MAMohammadreza Alivand
Mohammadreza Alivand
BABeitollah Alipour
Beitollah Alipour

1 January 2021 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
SDSoheila Delgir
Soheila Delgir
MBMilad Bastami
Milad Bastami
KIKhandan Ilkhani
Khandan Ilkhani
ASAsma Safi
Asma Safi
FSFarhad Seif
Farhad Seif
MAMohammad Reza Alivand
Mohammad Reza Alivand

15 June 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MAMaryam Abtin
Maryam Abtin
MAMohammad R. Alivand
Mohammad R. Alivand
MKMahmoud S. Khaniani
Mahmoud S. Khaniani
Milad BastamiMilad Bastami
Milad Bastami
MZMohammad Zaeifizadeh
Mohammad Zaeifizadeh
SDSima M. Derakhshan
Sima M. Derakhshan

17 January 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MZMaryam Zare
Maryam Zare
FJFerdous Rastgar Jazii
Ferdous Rastgar Jazii
MAMohammad Reza Alivand
Mohammad Reza Alivand
NNNegin Karimi Nasseri
Negin Karimi Nasseri
RMReza Malekzadeh
Reza Malekzadeh
MYMansour Yazdanbod
Mansour Yazdanbod
Background: Squamous cell carcinoma of esophagus (SCCE) occurs at a high incidence rate in certain parts of the world. This feature necessitates that different aspects of the disease and in particular genetic characteristics be investigated in such regions. In addition, such investigations might lead to achievement of molecular markers helpful for early detection, successful treatment and follow up of the disease. Adenomatous Polyposis Coli (APC) promoter hypermethylation has been shown to be a suitable marker for both serum and solid tumors of adenocarcinoma of esophagus. We investigated the status of APC promoter hypermethylation in Iranian patients, compared the results with the former studies, and evaluated its applicability as a candidate molecular marker by examining association between survival of SCCE patients and APC promoter methylation. Methods: For evaluating the status of APC promoter hypermethylation and its association with SCCE, a qualitative methylation specific PCR (MSP) was used. DNA was extracted and digested with an appropriate restriction enzyme, treated with sodium bisulfite in agarose beads and amplified in two-step PCR reaction by applying either methylated or unmethylated promoter specific primers. Universally methylated DNA and methylase treated blood DNA of healthy donors were used as positive controls as well. Survival of patients was followed up for two years after treatment and survival rate of patients with methylated APC promoter was compared with that of unmethylated patients. Results: Assessment of APC promoter methylation revealed that normal tissues were unmethylated, while twenty out of forty five (44.4%) tumor tissues were hypermethylated either in one or both alleles of APC. Among the tissues in which methylation was detected, seven were hypermethylated in both alleles while the other thirteen were hypermethylated in one of the two alleles of APC. Analyzing two-year survival rate of patients with respect to promoter hypermethylation showed a lower rate of survival for patients with methylated APC promoter following their treatment. Further investigation into the association between promoter hypermethylation and tumor differentiation status indicated that patients with well differentiated tumors were more likely to develop promoter hypermethylation. Conclusion: Observing similar level of APC promoter hypermethylation in patients with SCCE in this high risk region and comparing it with other parts of the world could support the hypothesis that a common molecular mechanism might be involved in tumorigenesis of SCCE. In addition, the higher rate of two-year survival for patients with unmethylated APC promoter as well as its relationship with tumor differentiation would suggest that this tumor suppressor could be an appropriate candidate molecular marker for evaluating tumor malignancy and predicting survival of patients subsequent to treatment.